Jump to main content
Jump to site search

All chapters
Previous chapter Next chapter


Kinase Inhibition for Immuno-oncology

A new era of immunotherapeutic intervention in oncology was ushered in by the approval of ipilimumab in 2011, a CTLA4 blocking antibody for the treatment of melanoma. The ensuing approval of several PD-(L)1 immune checkpoint-blockading agents demonstrated that durable responses could be realized in a disease where only a modest delay to progression was the standard outcome. All these therapeutic antibodies act through modulating the inter-cellular communication network employed by the immune system. However, such modalities are unsuited to attenuate intra-cellular signaling pathways, which currently remain the domain of small molecule therapeutics. Discussed herein are kinase targets and small molecule inhibitors thereof that have found utility in immuno-oncology. An emphasis in this review is placed on molecules and targets under clinical evaluation, although emerging areas of exciting preclinical biology will also be discussed.

Publication details

Print publication date
06 Nov 2018
Copyright year
Print ISBN
ePub eISBN
From the book series:
Drug Discovery